To use all functions of this page, please activate cookies in your browser.
Reducing costs and speeding up pre-clinical research
Sciomics GmbH was founded in the spring of 2013 as a spin-off company of the German Cancer Research Center (DKFZ) by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Since 2003, our team has gained experience with production and application of antibody microarrays as a tool for analysing complex protein samples. With this background, Sciomics is able to offer complete analysis of your samples with standardised as well as customised arrays.
Enabling Precision Medicinine through in-depth Protein and post-translational modification analysis
Our unique antibody microarray platform reduces costs and attrition rates in protein biomarker identification and verification projects. Thereby, we were able to establish a broad biomarker development pipeline for oncological indications as well as organ failure. Our protein biomarker signatures aim at a precise and detailed diagnosis for patient stratification in order to adapt the therapy exactly to the patient needs. Next to our internal development activities, we offer our customers scientific high-content protein profiling services. The analyses are usually based on our fixed content array portfolio (scioCyto, scioCD, scioDiscover) or custom protein arrays (scioSpot) are produced. The measurement of the abundance of more than 1,000 proteins can extended by a parallel analysis of the phosphorylation status (scioPhospho) or the ubiquitinylation status (scioUbi). Typical applications of our customers are - Biomarker discovery and verification studies - Drug target discovery and verification - Mode-of-Action Analysis - Pre-clinical assessment of novel compounds - Characterization and selection of cell culture or animal models - Pathway profiling and pathway activity analysis - Cytokine profiling - Immune response profiling